FDA批准首次治疗与Still's疾病有关的宏观活化综合症,带来了新的希望。 FDA approves first treatment for Macrophage Activation Syndrome linked to Still's Disease, offering new hope.

林业发展局已核准Empatalumab-lzsg(Gamifant)为与Still's病有关的宏观活化综合症(MAS)的首次治疗。 The FDA has approved Emapalumab-lzsg (Gamifant) as the first treatment for Macrophage Activation Syndrome (MAS) linked to Still's Disease. 该药物已于2018年被批准用于治疗HLH,通过阻塞干扰伽马,这是造成恶性炎的一个主要原因。 This drug, already approved for treating HLH in 2018, works by blocking interferon gamma, a key cause of hyperinflammation. 临床试验显示,50%以上的病人获得了完全的治疗,82%的病人在8周内获得缓解,为成人和儿童带来了新的希望。 Clinical trials showed over 50% of patients achieved a complete response, and 82% reached remission within eight weeks, offering new hope for both adults and children.